Pre-ASCO China Webinar #1 - Oncology Trial Conduct during COVID-19

First of the three webinars of "Pre-ASCO China Forum" focusing on conducting oncology clinical trials during COVID-19

About this Event

During COVID-19 pandemic, clinical trials are impacted globally. Cancer patients are among the hardest hit in and outside of oncology trial settings. We invited investigators, Profs. Jin Li, Caichun Zhou, Howard (Skip) Burris, Rebecca Heist, and Bob Li from both China and US to share their experience in managing clinical trials during COVID-19 and their approaches to minimizing impact on trial subjects and their clinical care. We also invited Dr. Tong Guo to discuss the use of digital tools to reduce physical interactions while maintaining trial conduct.

Webinar Date:

China Time: Saturday May 9th, 9 AM

US EST Time: Friday, May 8th, 9 PM

US PST Time: Friday, May 8th, 6 PM

Conference Language: English

Venue: Live Zoom Webcast

Webinar Agenda


Dr. Li Yan, Managing Director, US Chinese Anti-Cancer Association. CMO, Brii Biosciences

China Investigators

Prof. Jin Li, Department of Medical Oncology, Tongji University Shanghai East Hospital; immediate Past President of Chinese Society for Clinical Oncology

Prof. Caichun Zhou, Shanghai Pulmonary Hospital, Tongji University

US Investigators

Prof. Howard (Skip) Burris, President and Chief Medical Officer for Sarah Cannon Research Institute in Nashville

Prof. Rebecca Heist, Massachusetts General Hospital, Boston

Prof. Bob Li, Memorial Sloan Kettering Cancer Center, New York

Prof. Andre Goy, Hackensack University Medical Center

Digitized Site Management System in China

Dr. Tong Guo, CEO, Gem Flower Pharma Tech

► Q&A

Speakers Bio


Dr. Li Yan, Managing Director, US Chinese Anti-Cancer Association

Li Yan, MD/PhD, Chief Medical Officer of Brii Biosciences, is a seasoned drug developer. He held executive positions at GSK, Merck, and Johnson & Johnson, most recently, VP Global Oncology Head Unit Physician of GSK. He contributed to the development and approval of numerous medicines including Keytruda for China. His passion is to bring innovative medicines to transform patients’ lives, especially those in underprivileged communities. He firmly believes in the power of global collaboration. Li is a graduate of Peking University Medical College where he is an adjunct professor. He is an alumnus of Harvard Business School Enterprise Leadership program.


Prof. Jin Li, Shanghai Eastern Hospital; Chinese Society for Clinical Oncology

2016-Present: Professor of the Department of Oncology, Tongji University East Hospital, Shanghai, China

2003-2014: Professor and Director of the Department of Medical Oncology, Fudan University Cancer Hospital; Head, Clinical Study Unit of Fudan Cancer Hospital 2000

2002: Post-Doc and visiting scientist in Yale Medical School, USA

1997-1999: Associate professor in the Department of Oncology, ShanghaiChanghai Hospital

1989-1993: Attending and Lecturer in the Department of Obstetrics and Gynecology, Shanghai Changhai Hospital.

1982-1986: Resident in Xichang Railway Hospital in Sichuan Province.


Prof. Caichun Zhou, Shanghai Pulmonary Hospital

Caicun Zhou isthe Directorand Professor of the Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University, and Director of Tongji University Medical School Cancer Institute. He got his Ph.D degree from China Medical University and was further trained in Tokyo Chest Hospital for two years in 1990 and 1994 and worked as a visiting scientist for 6 months at MD Anderson Cancer Center in 2002. Hehas initiated or taken part in more than 100 multicenter clinical trials in the field of lung cancer including OPTIMAL, BEYOND, Alesia, Evidence and Keynote-033. His laboratory research focuses on the early diagnosis of lung cancer, genomic aberrations in lung cancers and identifying prognostic and predictive markers for chemotherapy, targeted therapy and anti-PD1/PDL1 immunotherapy in non-small cell lung cancers.

He has published more than330peer-reviewed papers including papers in Lancet Oncology and Journal of Clinical Oncology. He has also received more than 20 research grants from Chinese Government or Shanghai Government. As the leader of thoracic researchers in China, he established theChina Eastern-Western Lung Cancer Research Collaborative Group (E-West) and Thoracic Oncology Association of China International Exchange and Promotion Association for Medical and Healthcare.

He is an active member of IASLC and board of director of IASLC, Associate Editor of the IASLC Newsletterand former member of the IASLC Education Committee.He has held two IASLC Workshops in Shanghai and was actively involved in IASLC meetings including WCLC, IASLC-AACR joint conference, APLCC,and ELCC etc.


Prof. Howard (Skip) Burris, Chief Medical Officer for Sarah Cannon Research Institute in Nashville, American Society for Clinical Oncology

Howard A. "Skip" Burris III, MD, FASCO, FACP serves as president and chief medical officer of Sarah Cannon, as well as the executive director, drug development for the research institute. He is an associate of Tennessee Oncology, PLLC, where he practices medical oncology.

Dr. Burris' clinical research career has focused on the development of new cancer agents with an emphasis on first in human therapies, having led the trials of many novel antibodies, small molecules, and chemotherapies now FDA approved, including ado-trastuzumab emtansine, everolimus, and gemcitabine. In 1997, he established in Nashville the first community based early phase drug development program, which grew into the Sarah Cannon Research Institute. He has authored over 400 publications and 700 abstracts. Sarah Cannon has now dosed over 350 first in human anticancer therapies and enrolls more than 3000 patients per year into clinical trials.

Dr Burris was recently elected president of the American Society of Clinical Oncology (ASCO), a professional society representing over 40,000 cancer physicians and researchers globally. He also currently serves on the Board of ASCO’s Conquer Cancer Foundation. Additionally in 2014, Dr. Burris was selected by his peers as a Giant of Cancer Care for his achievements in drug development.

Dr. Burris completed his undergraduate education at the United States Military Academy at West Point, his medical degree at the University of South Alabama, and his internal medicine residency and oncology fellowship at Brooke Army Medical Center in San Antonio. While in Texas, he also served as the Director of Clinical Research at The Institute for Drug Development of the Cancer Therapy and Research Center and The University of Texas Health Science Center. He attained the rank of lieutenant colonel in the US Army, and among his decorations, he was awarded a Meritorious Service Medal with oak leaf cluster for his service in Operation Joint Endeavor.


Prof. Rebecca Heist, Massachusetts General Hospital, Boston

Rebecca S. Heist MD is an Associate Professor of Medicine at Harvard Medical School and Associate Director of Clinical Research at Massachusetts General Hospital Cancer Center. She is a thoracic oncologist with research interested in novel therapies for lung cancer and is an active member of the Termeer Center for Investigational Therapies at MGH.


Prof. Bob Li, Memorial Sloan Kettering Cancer Center, New York

Bob Li, MD, MPH, FRACP, is a medical oncologist and physician-scientist who specializes in lung cancers and early-phase drug development for solid tumors. He is also Co-Director of MSK’s multidisciplinary Thoracic Liquid Biopsy Program investigating the use of plasma biomarkers to optimize precision cancer therapy. His translational research in HER2-targeted basket trials has transformed national clinical practice guidelines, for which he has received awards from the American Society of Clinical Oncology and the American Association for Cancer Research. He has numerous scientific publications in prestigious journals such as Nature, Nature Medicine, Cancer Discovery, and Journal of Clinical Oncology. Dr. Li is an Australian who speaks fluent Chinese Mandarin and is Fellow of the Royal Australasian College of Physicians. As MSK’s Physician Ambassador to China and Asia-Pacific, he represents MSK on an official level and provides leadership in international patient care, research and education programs with China and the Asia-Pacific region. He works closely with colleagues at the International Center and hospital administration to advance MSK’s mission abroad with transparency and impact. Through compassionate care and international partnerships, his career is dedicated to winning the global war on cancer and bringing real hope to patients.


Prof. Andre Goy, Hackensack University Medical Center

Andre Goy, M.D. is HMH Physician in Chief, Hackensack Meridian Health Oncology Services and Chairman and Chief Physician Officer of John Theurer Cancer Center (“JTCC”) at Hackensack University Medical Center as well as Academic Chairman – Oncology at the Hackensack Meridian Health School of Medicine.

HMH Oncology Program encompasses 18 hospitals system including John Theurer Cancer Center (JTCC) at Hackensack University Medical Center (HUMC), a member of the National Cancer Institute (NCI)-designated Lombardi Comprehensive Cancer Center Consortium. JTCC provides the largest oncology program in New Jersey and is also a member of the Memorial Sloan Kettering - Hackensack Meridian Health partnership. Dr. Goy is also professor and Founding chair of the Department of Oncology at the Hackensack Meridian School of Medicine at Seton Hall University as well as Professor of Medicine at Georgetown University in Washington, DC.

Dr. Goy is widely known for his work in lymphoma, particularly in drug development in mantle cell lymphoma and other aggressive lymphomas. His research interest also includes the identification of prognostic markers and better ways to stratify patients with lymphoma. Dr. Goy has served on the steering committee for the NCI for lymphoma and on the Scientific Advisory Board of the Lymphoma Research Foundation. Dr. Goy and his team have been involved with the NCI for almost a decade in the development of new forms of immunotherapy, including checkpoint inhibitors in lymphoma and CAR T-cell therapy, leading to the first approval of CAR-T cells in lymphoma, in November 2017.

Dr. Goy believes that a true revolution is happening in cancer medicine, which will be driven by cell-based therapies /immunotherapy, precise medicine, earlier detection, analytics and connectivity. The bioinformatics platform developed at JTCC – called COTA – uses a unique classification system compressing all relevant individual patient data into a usable code (CNA). This digital architecture allows us to track individual outcome, optimize decisions in cancer care, and hence reduce adverse variance in order to improve outcome at the individual level, while lowering costs for the population along the way and supporting value-based care initiatives.

Dr. Goy has published more than 180 peer reviewed papers and serves as reviewer for many journals in the field including the New England Journal of Medicine, the Journal of Clinical Oncology, and Blood, the American Society of Hematology Journal, among others. He has been the co-chair of the Global Council on the Future of Health and Healthcare for the World Economic Forum since 2015. He believes that we are at an inflection point in medicine due to unprecedented combination of rapid progress in science and discovery, but also technology which will help reshape both health and healthcare delivery.

Dr. Goy received his medical degree from University Joseph Fourier in Grenoble, France before completing his training in hematology oncology in Paris at the Faculté of Medicine Cochin Port Royal. While there he also received a Master’s degree in Tumor Immunology from Pasteur Institute and Curie University Paris VI as well as a Master’s degree in Experimental Oncology from University Kremlin Bicetre. Dr. Goy was on faculty at Memorial Sloan-Kettering and M.D. Anderson Cancer Center before joining John Theurer Cancer Center in 2005. Dr. Goy has been leading the Lymphoma Program at JTCC, he became Chair and Director of JTCC in 2012, and has been appointed as Physician in Chief for Hackensack Meridian Health, the largest, most comprehensive and truly integrated health care network in New Jersey, with 18 hospitals from Bergen to Ocean counties.


Dr. Tong Guo, CEO, Gem Flower Pharma Tech

Dr. Tong Guo is the CEO of Gem Flower Pharma Tech., an ARO based in Beijing. Dr. Guo was Vice President and Head of Business Development China at IQVIA. Prior to his BD role, Dr. Guo was the Head of Biostatistics Africa & Asia and managed the off-shore Biostatistics functions at legacy Quintiles. Before joining IQVIA, Dr. Guo used to work as the Head of Global Data Sciences & Analytics Beijing R&D Center at Bayer HealthCare; Vice-President and Head of Clinical Informatics & FSP at WuXiPRA. Dr. Guo began his clinical research career in 1998 as a Biostatistician at McMaster University in Ontario, Canada. He was a Biostatistician in the United States in both CRO (MDS Pharma Services) and pharmaceutical companies (Bristol-Myers Squibb and Johnson & Johnson) with increasing responsibilities. Tong received his M.Sc and Ph.D. degrees in Biostatistics from McGill University, Montreal Canada.



US Chinese Anti-Cancer Association

U.S. Chinese Anti-Cancer Association (USCACA) is a non-profit professional organization founded in 2009. With members from academia, industry and government, USCACA facilitates collaboration among cancer research and physicians in the United States and China. Our current focus is on expediting novel cancer drug development by fostering clinical trial networks, sharing best practices and knowledge of clinical trial, and providing education and training opportunities. USCACA collaborates with Chinese Anti-Cancer Association, Chinese Society for Clinical Oncology, and other professional associations. Our mandate is to improve cancer treatment through research, education, and collaboration.


eChinaHealth is an integrated media for China healthcare and pharmaceutical segments. eChinaHealth services include digital platform and media, conferences and events, data and consulting, and social network and community.

eChinaHealth is exclusive China sale representation for ASCO Publications including “Journal of Clinical Oncology”, “Journal of Clinical Practice”, and “ASCO Post”, etc. eChinaHealth and ASCO plan to organize a series of ASCO Direct™ conference in China. The ASCO Direct™ program is an educational initiative that condenses highlights from ASCO Meeting into a 1-day China program, in an effort to provide Chinese doctors’ access to the most cutting-edge research discussed at ASCO meetings.




BeiGene is a biopharmaceutical company focused on developing molecularly targeted and immuno-oncology drug candidates for the treatment of cancer. Our mission is to become a global leader in the discovery, development, and commercialization of innovative, molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.


Welcome to john the ASCO China Conference WeChat Groups! You can follow up the latest on ASCO China conferences and network with fellow Chinese and global attendees. We will post the conference information including the links on recorded conference videos. Please use your WeChat to scan the QR code to join.